Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Autologous T cell therapy against CD19: Phase Ib/II started

October 10, 2016 7:00 AM UTC

Kite began the open-label, U.S. Phase Ib/II ZUMA-6 trial to evaluate IV KTE-C19 plus Tecentriq atezolizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) in about 31 patients. After receiving a conditioning chemotherapy regimen of fludarabine and cyclophosphamide, patients will receive KTE-C19 followed by Tecentriq, a human mAb against PD-L1. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article